Last reviewed · How we verify

Peripheral Edema due to Chronic Heart Failure — Treatment Landscape & Competitive Intelligence

Peripheral Edema due to Chronic Heart Failure (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peripheral Edema due to Chronic Heart Failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zaroxolyn METOLAZONE I3 Pharms Thiazide-like Diuretic [EPC] Carbonic anhydrase 7 1973-01-01
Edecrin ETHACRYNIC ACID Bausch Health Loop Diuretic [EPC] Glutathione S-transferase P 1967-01-01
Lasix furosemide Generic (originally Hoechst AG) Loop Diuretic [EPC] ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 1966-07-01
Aldactone spironolactone Generic (originally Searle/Pfizer) Aldosterone Antagonist [EPC] Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2 1960-01-01
Combipres Chlortalidone University Hospital Birmingham Thiazide-like Diuretic Carbonic anhydrase 7 1960-01-01
Microzide hydrochlorothiazide Generic (originally Merck) Thiazide Diuretic [EPC] ACE 1959-01-01
Diuril CHLOROTHIAZIDE Salix Pharms Thiazide Diuretic Solute carrier family 12 member 3 1958-01-01
Diamox ACETAZOLAMIDE Teva Carbonic Anhydrase Inhibitor [EPC] Carbonic anhydrase 1953-01-01
Spironolacton Spironolacton ACS Biomarker Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2
Frusemide Frusemide Melbourne Health ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Peripheral Edema due to Chronic Heart Failure
  2. ACS Biomarker · 1 drug in Peripheral Edema due to Chronic Heart Failure
  3. Bausch Health · 1 drug in Peripheral Edema due to Chronic Heart Failure
  4. Generic (originally Hoechst AG) · 1 drug in Peripheral Edema due to Chronic Heart Failure
  5. Generic (originally Merck) · 1 drug in Peripheral Edema due to Chronic Heart Failure
  6. Generic (originally Searle/Pfizer) · 1 drug in Peripheral Edema due to Chronic Heart Failure
  7. I3 Pharms · 1 drug in Peripheral Edema due to Chronic Heart Failure
  8. Medical University of Warsaw · 1 drug in Peripheral Edema due to Chronic Heart Failure
  9. Melbourne Health · 1 drug in Peripheral Edema due to Chronic Heart Failure
  10. Salix Pharms · 1 drug in Peripheral Edema due to Chronic Heart Failure
  11. Second Xiangya Hospital of Central South University · 1 drug in Peripheral Edema due to Chronic Heart Failure
  12. Teva · 1 drug in Peripheral Edema due to Chronic Heart Failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peripheral Edema due to Chronic Heart Failure:

Cite this brief

Drug Landscape (2026). Peripheral Edema due to Chronic Heart Failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-edema-due-to-chronic-heart-failure. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing